Novozymes A/S

Novozymes A/S is a global leader in biosolutions, specializing in enzymes and microorganisms that enhance efficiency in various industries, supporting sustainability and health. Founded in Denmark, Novozymes A/S focuses on providing biological solutions to industrial challenges. The company has not undergone significant pivots in its strategy or operations. It operates globally with headquarters in Bagsværd, Denmark.

The founder, Tigran Mirzoyan, is known for his expertise in the biotechnology sector. Novozymes specializes in biosolutions that utilize biological processes to solve challenges across multiple industries. Its core offerings include enzymes, fermented proteins, and microorganisms aimed at enhancing production efficiency, food safety, human health, and supporting environmental sustainability. The company's products serve over 30 industries, including food and beverages, agricultural and industrial applications, household care, and animal health and nutrition.

Novozymes products are utilized worldwide, with significant markets in North America, Europe, and Asia, allowing for localized solutions that meet regional customer needs. In 2023, Novozymes reported a revenue of USD 2,598. 49 mn and an EBITDA of USD 778. 86 mn.

The company's revenue is generated through B2B transactions, built on long-term partnerships and collaborations, with tailored biosolutions supplied to clients across various sectors, primarily through direct sales of proprietary enzymes and functional proteins. Novozymes A/S is committed to expanding its product lineup with upcoming launches focused on enhancing sustainability and efficiency. The company aims to penetrate new markets, particularly in Asia and South America, by 2025. Recent funding will be allocated to support research and development efforts to innovate and expand their product offerings.